During the past decade, SPZOZ Centralny Szpital Kliniczny UM w Lodzi conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 5 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 5 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "SPZOZ Centralny Szpital Kliniczny UM w Lodzi" #1 sponsor was "Takeda" with 3 trials, followed by "Abbott Medical Devices" with 2 trials sponsored, "Amgen" with 2 trials sponsored, "Biogen" with 2 trials sponsored and "Janssen Research & Development, LLC" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "SPZOZ Centralny Szpital Kliniczny UM w Lodzi" #1 collaborator was "Canadian VIGOUR Centre" with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "Population Health Research Institute" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "SPZOZ Centralny Szpital Kliniczny UM w Lodzi" are "Alzheimer's Disease" (2 trials), "Atrial Fibrillation" (2 trials), "Depressive Disorder, Major" (2 trials), "Type 1 Diabetes Mellitus" (2 trials) and "Active Juvenile Psoriatic Arthritis" (1 trials). Many other conditions were trialed in "SPZOZ Centralny Szpital Kliniczny UM w Lodzi" in a lesser frequency.

Most popular intervention types in "SPZOZ Centralny Szpital Kliniczny UM w Lodzi" are "Drug" (18 trials), "Device" (2 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Aticaprant" (2 trials), "Aducanumab" (1 trials), "Aducanumab (BIIB037)" (1 trials) and "Alternative osteoporosis medications" (1 trials). Other intervention names were less common.

The vast majority of trials in "SPZOZ Centralny Szpital Kliniczny UM w Lodzi" are 21 trials for "All" genders.

Currently, there are NaN active trials in "SPZOZ Centralny Szpital Kliniczny UM w Lodzi". undefined are not yet recruiting, 11 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in SPZOZ Centralny Szpital Kliniczny UM w Lodzi, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in SPZOZ Centralny Szpital Kliniczny UM w Lodzi, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".